Perceive Biotherapeutics CEO Angela Macfarlane (L) and president Anne Rubin
January 6, 2023 06:25 AM ESTUpdated 09:48 AM
Financing

Up­dat­ed: Stealth biotech Per­ceive rais­es $78M from J&J and Deer­field, says lit­tle about eye dis­ease pro­grams

Lei Lei Wu

News Reporter

Eye dis­ease biotech Per­ceive Bio­ther­a­peu­tics an­nounced Thurs­day that it has raised $78 mil­lion in a Se­ries B, though it says it is re­main­ing in stealth …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times